{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:09:31Z","timestamp":1793642971784,"version":"4.5.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Society of Endocrinology and Metabolism of Turkey","award":["04\/10\/2016-01"],"award-info":[{"award-number":["04\/10\/2016-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians\u2019 attitudes on the treatment of diabetic dyslipidemia were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70\u2009mg\/dL for patients with macrovascular complications or diabetic nephropathy, and below 100\u2009mg\/dL for other patients. Data about lipid-lowering medications were self-reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73\u2009\u00b1\u20091.74% and 10.9\u2009\u00b1\u20097.5\u2009years, respectively. The need for statin treatment was 94.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094262); however, only 42.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091807) of these patients were under treatment, and only 24.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59\u20130.83).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-020-01408-2","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T09:03:09Z","timestamp":1605085389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)"],"prefix":"10.1186","volume":"19","author":[{"name":"TEMD Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Bayram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Sonmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-2364","authenticated-orcid":false,"given":"Cem","family":"Haymana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Sabuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzhan Sitki","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Gurkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Kargili","family":"Carlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Agbaht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Barcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Tetiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Kemal","family":"Balci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Kebapci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Satman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","volume":"100","author":"SM Grundy","year":"1999","unstructured":"Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134\u201346.","journal-title":"Circulation."},{"key":"1408_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet Diabetes Endocrinol. 2015;3:105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1408_CR3","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353. https:\/\/pubmed.ncbi.nlm.nih.gov\/9742976\/.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"1408_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"TD Control","year":"1993","unstructured":"Control TD, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"1408_CR5","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"1408_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1408_CR7","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P G\u00e6de","year":"2016","unstructured":"G\u00e6de P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298\u2013307.","journal-title":"Diabetologia."},{"key":"1408_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)12475-0","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleight P, Peto R, Group HPSC. MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005\u201316.","journal-title":"Lancet."},{"key":"1408_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1408_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","volume":"316","author":"RC Turner","year":"1998","unstructured":"Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316:823\u20138.","journal-title":"BMJ."},{"key":"1408_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886\u201399.","journal-title":"Diabetologia."},{"key":"1408_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOL.0000000000000318","volume":"27","author":"H Soran","year":"2016","unstructured":"Soran H, Schofield JD, Adam S, Durrington PN. Diabetic dyslipidaemia. Curr Opin Lipidol. 2016;27:313\u201322.","journal-title":"Curr Opin Lipidol"},{"key":"1408_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet."},{"key":"1408_CR14","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","volume":"98","author":"RB Goldberg","year":"1998","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, Moy\u00e9 LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98:2513\u20139.","journal-title":"Circulation"},{"key":"1408_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2015.03.020","volume":"37","author":"BR Pauff","year":"2015","unstructured":"Pauff BR, Jiroutek MR, Holland MA, Sutton BS. Statin prescribing patterns: an analysis of data from patients with diabetes in the National Hospital Ambulatory Medical Care Survey Outpatient Department and National Ambulatory Medical Care Survey Databases, 2005-2010. Clin Ther. 2015;37:1329\u201339.","journal-title":"Clin Ther"},{"key":"1408_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","volume":"39","author":"JG Kuiper","year":"2017","unstructured":"Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, et al. Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017;39:819\u201327 e1.","journal-title":"Clin Ther"},{"key":"1408_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W M\u00e4rz","year":"2018","unstructured":"M\u00e4rz W, Dippel F-W, Theobald K, Gorcyca K, Iorga \u015eR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99\u2013107.","journal-title":"Atherosclerosis."},{"key":"1408_CR18","doi-asserted-by":"publisher","first-page":"12648","DOI":"10.1038\/s41598-017-13066-z","volume":"7","author":"X Zhang","year":"2017","unstructured":"Zhang X, Ji L, Ran X, Su B, Ji Q, Hu D. Gender disparities in lipid goal attainment among type 2 diabetes outpatients with coronary heart disease: results from the CCMR-3B study. Sci Rep. 2017;7:12648\u20137.","journal-title":"Sci Rep"},{"key":"1408_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013255","volume":"7","author":"DL Steen","year":"2017","unstructured":"Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for health and care excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017;7:e013255.","journal-title":"BMJ Open"},{"key":"1408_CR20","first-page":"107424841989929","volume":"46","author":"X Wang","year":"2020","unstructured":"Wang X, He Y, Wang T, Li C, Ma Z, Zhang H, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou. China J Cardiovasc Pharmacol Ther. 2020;46:1074248419899298.","journal-title":"China J Cardiovasc Pharmacol Ther"},{"key":"1408_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","volume":"251","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis. 2016;251:248\u201354.","journal-title":"Atherosclerosis."},{"key":"1408_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/clc.22641","volume":"40","author":"DL Steen","year":"2017","unstructured":"Steen DL, Khan I, Becker L, Foody JM, Gorcyca K, Sanchez RJ, et al. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: insights from a large US managed-care population. Clin Cardiol. 2017;40:155\u201362.","journal-title":"Clin Cardiol"},{"key":"1408_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","volume":"255","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016;255:200\u20139.","journal-title":"Atherosclerosis."},{"key":"1408_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.diabres.2012.05.003","volume":"98","author":"I Satman","year":"2012","unstructured":"Satman I, Imamoglu S, Yilmaz C, ADMIRE Study Group. A patient-based study on the adherence of physicians to guidelines for the management of type 2 diabetes in Turkey. Diabetes Res Clin Pract. 2012;98:75\u201382.","journal-title":"Diabetes Res Clin Pract"},{"key":"1408_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.diabres.2018.09.010","volume":"146","author":"A Sonmez","year":"2018","unstructured":"Sonmez A, Haymana C, Bayram F, Salman S, Dizdar OS, Gurkan E, et al. Turkish nationwide survEy of glycemic and other metabolic parameters of patients with diabetes mellitus (TEMD study). Diabetes Res Clin Pract. 2018;146:138\u201347.","journal-title":"Diabetes Res Clin Pract"},{"key":"1408_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4274\/tjem.3120","volume":"20","author":"H \u0130lkova","year":"2016","unstructured":"\u0130lkova H, Damc\u0131 T, Kar\u015f\u0131da\u011f K, \u00c7\u00f6mlek\u00e7i A, Ayvaz G. The international diabetes management practices study (IDMPS) - Turkey\u2019s 5th wave results. Turk J Endocrinol Metab. 2016;20:88\u201396.","journal-title":"Turk J Endocrinol Metab"},{"key":"1408_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"1408_CR28","volume-title":"Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and Its Complications-2017. 9th Edition","author":"SEMT Diabetes Mellitus Study Group","year":"2017","unstructured":"SEMT Diabetes Mellitus Study Group. Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and Its Complications-2017. 9th Edition, 2017. ISBN: 978-605-4011-26-1."},{"key":"1408_CR29","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017;40:S11\u201324. https:\/\/pubmed.ncbi.nlm.nih.gov\/27979889\/.","DOI":"10.2337\/dc17-S005"},{"key":"1408_CR30","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"key":"1408_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Casula M, Badimon L, Chapman MJ, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1408_CR32","volume-title":"Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and Its Complications-2020. 14th Edition","author":"SEMT Diabetes Mellitus Study Group","year":"2020","unstructured":"SEMT Diabetes Mellitus Study Group. Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and Its Complications-2020. 14th Edition, 2020. ISBN: 978-605-4011-40-7."},{"key":"1408_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/03007995.2016.1239190","volume":"33","author":"E Heintjes","year":"2017","unstructured":"Heintjes E, Kuiper J, Lucius B, Penning-van Beest F, Kutikova L, Liem A, et al. Characterization and cholesterol management in patients with cardiovascular events and\/or type 2 diabetes in the Netherlands. Curr Med Res Opin. 2017;33:91\u2013100.","journal-title":"Curr Med Res Opin"},{"issue":"36","key":"1408_CR34","first-page":"A5104","volume":"156","author":"T Wiersma","year":"2012","unstructured":"Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. Samenvatting van de multidisciplinaire richtlijn 'Cardiovasculair risicomanagement' (herziening 2011) [summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)]. Ned Tijdschr Geneeskd. 2012;156(36):A5104.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1408_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1185\/03007995.2013.803053","volume":"29","author":"A Oguz","year":"2013","unstructured":"Oguz A, Benroubi M, Brismar K, Melo P, Morar C, Cleall SP, et al. Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Curr Med Res Opin. 2013;29:911\u201320.","journal-title":"Curr Med Res Opin"},{"key":"1408_CR36","first-page":"287","volume":"62","author":"N Kahya Eren","year":"2014","unstructured":"Kahya Eren N, Harman E, Dolek D, Emren S, T\u00fct\u00fcnc\u00fco\u011flu AP, Nazli C, et al. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey. Minerva Cardioangiol. 2014;62:287\u201395.","journal-title":"Minerva Cardioangiol"},{"key":"1408_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1262-3636(07)70124-6","volume":"30","author":"T Damci","year":"2004","unstructured":"Damci T, Kultursay H, Oguz A, Pehlivanoglu S, Tokgozoglu L, Vascular risk study group. Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes Metab. 2004;30:327\u201333.","journal-title":"Diabetes Metab"},{"issue":"4","key":"1408_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4158\/EP171764.GL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease - Executive Summary. Endocr Pract. 2017;23(4):479\u201397.","journal-title":"Endocr Pract"},{"key":"1408_CR39","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.clinthera.2008.11.004","volume":"30","author":"LW Segars","year":"2008","unstructured":"Segars LW, Lea AR. Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national, cross-sectional study. Clin Ther. 2008;30:2159\u201366.","journal-title":"Clin Ther"},{"key":"1408_CR40","doi-asserted-by":"publisher","first-page":"i3283","DOI":"10.1136\/bmj.i3283","volume":"353","author":"A Matthews","year":"2016","unstructured":"Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.","journal-title":"BMJ."},{"key":"1408_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5694\/mja15.00103","volume":"202","author":"AL Schaffer","year":"2015","unstructured":"Schaffer AL, Buckley NA, Dobbins TA, Banks E, Pearson S-A. The crux of the matter: did the ABC's catalyst program change statin use in Australia? Med J Aust. 2015;202:591\u20135.","journal-title":"Med J Aust"},{"key":"1408_CR42","first-page":"731","volume":"45","author":"C Haymana","year":"2017","unstructured":"Haymana C, Berlik H, G\u00fcne\u015f Y, Tun\u00e7ez OE, Aytekin C, Tap\u0131kara Z, et al. Identifying undiagnosed or undertreated patients with familial hypercholesterolemia from the laboratory records of a tertiary medical center. Turk Kardiyol Dern Ars. 2017;45:731\u20138.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"1408_CR43","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2016","unstructured":"Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37:908\u201316.","journal-title":"Eur Heart J"},{"key":"1408_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/eurheartj\/ehx789","volume":"39","author":"BG Nordestgaard","year":"2018","unstructured":"Nordestgaard BG. Why do the media report negative news about statins? Eur Heart J. 2018;39:337\u20138.","journal-title":"Eur Heart J"},{"key":"1408_CR45","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","volume":"105","author":"U Laufs","year":"2016","unstructured":"Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol. 2016;105:783\u201390.","journal-title":"Clin Res Cardiol"},{"key":"1408_CR46","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/nu5041218","volume":"5","author":"B Klop","year":"2013","unstructured":"Klop B, Elte J, Elte JWF, Cabezas M, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5:1218\u201340.","journal-title":"Nutrients."},{"key":"1408_CR47","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa020194","volume":"347","author":"WE Kraus","year":"2002","unstructured":"Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483\u201392.","journal-title":"N Engl J Med"},{"key":"1408_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ijcard.2016.02.015","volume":"209","author":"D De Smedt","year":"2016","unstructured":"De Smedt D, De Bacquer D, De Sutter J, Dallongeville J, Gevaert S, De Backer G, et al. The gender gap in risk factor control: effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol. 2016;209:284\u201390.","journal-title":"Int J Cardiol"},{"key":"1408_CR49","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ahj.2006.05.013","volume":"152","author":"BJ Ansell","year":"2006","unstructured":"Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH, et al. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006;152:976\u201381.","journal-title":"Am Heart J"},{"key":"1408_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ahj.2013.02.011","volume":"165","author":"J Lewey","year":"2013","unstructured":"Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165:665\u201378 678.e1.","journal-title":"Am Heart J"},{"key":"1408_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00228-015-1980-2","volume":"72","author":"P Ballo","year":"2016","unstructured":"Ballo P, Balzi D, Barchielli A, Turco L, Franconi F, Zuppiroli A. Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting. Eur J Clin Pharmacol. 2016;72:311\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1408_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in patient education (USAGE) study. J Clin Lipidol. 2016;10:833\u201341.","journal-title":"J Clin Lipidol"},{"key":"1408_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","volume":"28","author":"I Satman","year":"2013","unstructured":"Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28:169\u201380.","journal-title":"Eur J Epidemiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-020-01408-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T09:15:19Z","timestamp":1605086119000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01408-2","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"28 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by The Central Ethical Committee (Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency, 14- MAR- 2017\/93189304\u2013514.11.01-E.58933).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest within the context of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}